文献速递认知障碍与痴呆

阿尔茨海默病痴呆转化相关模式作为神经变性ATN生物标志物的验证

Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
PubMed 文献 · Neurology · 2021-01-06

本研究纳入269例有[18F]FDG PET、[18F]AV-45 PET、脑脊液磷酸化及总tau和血浆神经丝轻链数据的患者,按AT(N)分类。结果发现ADCRP个体评分在A+T+组显著高于其他组,且在A+T+组中可显著预测痴呆转化(风险比2.02每z评分增加,p<0.001),预测价值优于总tau和神经丝轻链。

要点

  • ADCRP评分在生物学定义的AD(A+T+)患者中显著升高。
  • ADCRP评分可预测MCI患者向AD痴呆转化,风险比2.02每z评分增加。
  • ADCRP预测转化优于总tau和神经丝轻链等神经变性标志物。

核心结论

  • ADCRP是MCI且生物学定义为AD患者中有价值的神经变性生物标志物,可用于风险分层和估计痴呆转化时间。

研究设计与样本

  • 研究纳入269例有[18F]FDG PET、[18F]AV-45 PET、脑脊液磷酸化及总tau和血浆神经丝轻链数据的患者,按AT(N)分类分为A-T-、A+T-、A+T+(AD)和A-T+组。

主要发现

  • ADCRP平均个体评分在A+T+组显著高于其他各组(均p<0.05),而其他组间相似(均p>0.1)。
  • 在A+T+组内,ADCRP个体评分是痴呆转化的显著预测因子(风险比2.02每z评分增加;p<0.001)。
  • ADCRP预测价值高于总tau和神经丝轻链等替代神经变性标志物。
  • 按ADCRP个体评分对A+T+患者分层,可区分高、中、低转化风险组。

关键数值与推荐

  • ADCRP个体评分每增加1个z评分,痴呆转化风险比2.02(p<0.001)。
  • ADCRP评分在A+T+组与其他组比较均p<0.05,其他组间比较均p>0.1。

临床怎么用

  • 对于MCI且AT(N)分类为A+T+的患者,可考虑使用[18F]FDG PET衍生的ADCRP评分进行痴呆转化风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether the Alzheimer disease (AD) dementia conversion-related pattern (ADCRP) on [18F]FDG PET can serve as a valid predictor for the development of AD dementia, the individual expression of the ADCRP (subject score) and its prognostic value were examined in patients with mild cognitive impairment (MCI) and biologically defined AD. METHODS: A total of 269 patients with available [18F]FDG PET, [18F]AV-45 PET, phosphorylated and total tau in CSF, and neurofilament light chain in plasma were included. Following the AT(N) classification scheme, where AD is defined biologically by in vivo biomarkers of β-amyloid (Aβ) deposition ("A") and pathologic tau ("T"), patients were categorized to the A-T-, A+T-, A+T+ (AD), and A-T+ groups. RESULTS: The mean subject score of the ADCRP was significantly higher in the A+T+ group compared to each of the other group (all p < 0.05) but was similar among the latter (all p > 0.1). Within the A+T+ group, the subject score of ADCRP was a significant predictor of conversion to dementia (hazard ratio, 2.02 per z score increase; p < 0.001), with higher predictive value than of alternative biomarkers of neurodegeneration (total tau and neurofilament light chain). Stratification of A+T+ patients by the subject score of ADCRP yielded well-separated groups of high, medium, and low conversion risks. CONCLUSIONS: The ADCRP is a valuable biomarker of neurodegeneration in patients with MCI and biologically defined AD. It shows great potential for stratifying the risk and estimating the time to conversion to dementia in patients with MCI and underlying AD (A+T+). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that [18F]FDG PET predicts the development of AD dementia in individuals with MCI and underlying AD as defined by the AT(N) framework.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Blazhenets G, Frings L, Ma Y, et al. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology. 2021. PMID: 33408150. doi:10.1212/WNL.0000000000011521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。